Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Analytical, practical and regulatory issues in prevention studies.

Susan S Ellenberg1

  • 1Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, FDA, 1401 Rockville Pike, HFM-210, Rockville, MD 20852, USA. ellenberg@cber.fda.gov

Statistics in Medicine
|January 13, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Establishing minimally important difference thresholds for lesion counts in acne clinical studies.

Journal of the American Academy of Dermatology·2025
Same author

Interim Clinical Trial Data: Who Can See What, and When?

Therapeutic innovation & regulatory science·2025
Same author

Modulation of circulating free testosterone fraction by testosterone, dihydrotestosterone, and estradiol during testosterone replacement therapy.

Andrology·2024
Same author

Pulmonary Hypertension and Anastrozole (PHANTOM): A Randomized, Double-Blind, Placebo-Controlled Trial.

American journal of respiratory and critical care medicine·2024
Same author

Methods for the estimation of direct and indirect vaccination effects by combining data from individual- and cluster-randomized trials.

Statistics in medicine·2024
Same author

Early Termination of Clinical Trials for Futility - Considerations for a Data and Safety Monitoring Board.

NEJM evidence·2024

Prevention studies, particularly for chronic diseases, face unique challenges. Ensuring participant safety and robust data in large trials with healthy individuals is critical for success.

Area of Science:

  • Clinical Trials
  • Preventive Medicine
  • Public Health

Background:

  • Prevention studies differ from treatment studies, with significant experience in infectious disease vaccines.
  • Vaccine research is expanding into areas like cancer prevention, but success is limited outside infectious diseases.
  • Enrollment of healthy individuals in prevention trials necessitates stringent safety standards.

Purpose of the Study:

  • To highlight the distinct challenges in designing and conducting prevention studies.
  • To emphasize the critical need for high safety standards when enrolling healthy participants.
  • To discuss methodological considerations for large-scale prevention trials.

Main Methods:

  • Acknowledging the need for simplified approaches in large trials to maintain data quality.

Related Experiment Videos

  • Underscoring the importance of reliable randomization and blinding to minimize bias.
  • Addressing the use of biomarkers as endpoints and challenges in specific populations like the elderly.

    • Main Results:

    • Prevention studies, especially for uncommon diseases, often require large sample sizes.
    • Compromises in data collection frequency and scope may be necessary in large trials.
    • Bias can easily negate small effects, making methodological rigor paramount.

    Conclusions:

    • Prevention research demands meticulous planning regarding participant safety and data integrity.
    • Methodological adaptations are essential for the successful execution of large prevention trials.
    • Addressing complexities in specific populations, like older adults, is crucial for effective preventive strategies.